{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T00:20:22Z","timestamp":1760833222815,"version":"build-2065373602"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s40261-025-01478-z","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T05:23:53Z","timestamp":1758605033000},"page":"825-836","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mucous Membrane Pemphigoid Outcome Measurement in Clinical Research: A Scoping Review"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7404-010X","authenticated-orcid":false,"given":"Billal","family":"Tedbirt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9166-5654","authenticated-orcid":false,"given":"Eva W. H.","family":"Korte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7715-1697","authenticated-orcid":false,"given":"Marjolein A. J.","family":"Hiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7654-3528","authenticated-orcid":false,"given":"Joost M.","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2086-9363","authenticated-orcid":false,"given":"Maria C.","family":"Bolling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6035-2863","authenticated-orcid":false,"given":"Phyllis I.","family":"Spuls","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5856-7657","authenticated-orcid":false,"given":"Sjoukje","family":"van der Werf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6722-3569","authenticated-orcid":false,"given":"Marc","family":"Yale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8559-3674","authenticated-orcid":false,"given":"Barbara","family":"Horv\u00e1th","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5734-0255","authenticated-orcid":false,"given":"Pascal","family":"Joly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,23]]},"reference":[{"issue":"10","key":"1478_CR1","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1111\/jdv.17395","volume":"35","author":"E Schmidt","year":"2021","unstructured":"Schmidt E, Rashid H, Marzano AV, et al. European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology-part II. J Eur Acad Dermatol Venereol JEADV. 2021;35(10):1926\u201348. https:\/\/doi.org\/10.1111\/jdv.17395.","journal-title":"J Eur Acad Dermatol Venereol JEADV."},{"issue":"9","key":"1478_CR2","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1111\/jdv.17397","volume":"35","author":"H Rashid","year":"2021","unstructured":"Rashid H, Lamberts A, Borradori L, et al. European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology-part I. J Eur Acad Dermatol Venereol. 2021;35(9):1750\u201364. https:\/\/doi.org\/10.1111\/jdv.17397.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1478_CR3","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1001\/archderm.138.3.370","volume":"138","author":"LS Chan","year":"2002","unstructured":"Chan LS, Ahmed AR, Anhalt GJ, et al. The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol. 2002;138(3):370\u20139. https:\/\/doi.org\/10.1001\/archderm.138.3.370.","journal-title":"Arch Dermatol"},{"key":"1478_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/lary.20763","author":"T Higgins","year":"2010","unstructured":"Higgins T, Cohen J, Sinacori J. Laryngeal mucous membrane pemphigoid: a systematic review and pooled-data analysis. Laryngoscope. 2010. https:\/\/doi.org\/10.1002\/lary.20763.","journal-title":"Laryngoscope"},{"issue":"2","key":"1478_CR5","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.oooo.2015.01.024","volume":"120","author":"J Taylor","year":"2015","unstructured":"Taylor J, McMillan R, Shephard M, et al. World Workshop on Oral Medicine VI: a systematic review of the treatment of mucous membrane pemphigoid. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015;120(2):161-171.e20. https:\/\/doi.org\/10.1016\/j.oooo.2015.01.024.","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"1478_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1323334","author":"Y Guo","year":"2023","unstructured":"Guo Y, Zhao H, Ren M, Wang Y, Wang L, Tang L. Efficacy and safety of rituximab in elderly patients with membranous nephropathy. Front Pharmacol. 2023. https:\/\/doi.org\/10.3389\/fphar.2023.1323334.","journal-title":"Front Pharmacol"},{"key":"1478_CR7","doi-asserted-by":"publisher","unstructured":"Suarez-Almazor ME, Belseck E, Shea B, Wells G, Tugwell P. Cyclophosphamide for treating rheumatoid arthritis. Cochrane Database Syst Rev. 2000;(4):CD001157. https:\/\/doi.org\/10.1002\/14651858.CD001157","DOI":"10.1002\/14651858.CD001157"},{"issue":"Suppl 3","key":"1478_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-017-1978-4","volume":"18","author":"PR Williamson","year":"2017","unstructured":"Williamson PR, Altman DG, Bagley H, et al. The COMET handbook: version 1.0. Trials. 2017;18(Suppl 3):280. https:\/\/doi.org\/10.1186\/s13063-017-1978-4.","journal-title":"Trials"},{"issue":"1","key":"1478_CR9","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1186\/s13063-016-1555-2","volume":"17","author":"CAC Prinsen","year":"2016","unstructured":"Prinsen CAC, Vohra S, Rose MR, et al. How to select outcome measurement instruments for outcomes included in a \u201cCore Outcome Set\u201d\u2014a practical guideline. Trials. 2016;17(1):449. https:\/\/doi.org\/10.1186\/s13063-016-1555-2.","journal-title":"Trials"},{"issue":"1","key":"1478_CR10","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jaad.2014.08.024","volume":"72","author":"DF Murrell","year":"2015","unstructured":"Murrell DF, Marinovic B, Caux F, et al. Definitions and outcome measures for mucous membrane pemphigoid: recommendations of an international panel of experts. J Am Acad Dermatol. 2015;72(1):168\u201374. https:\/\/doi.org\/10.1016\/j.jaad.2014.08.024.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1478_CR11","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jaad.2020.12.056","volume":"87","author":"Y Lytvyn","year":"2022","unstructured":"Lytvyn Y, Rahat S, Mufti A, et al. Biologic treatment outcomes in mucous membrane pemphigoid: a systematic review. J Am Acad Dermatol. 2022;87(1):110\u201320. https:\/\/doi.org\/10.1016\/j.jaad.2020.12.056.","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl 1(Suppl 1","key":"1478_CR12","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/odi.13083","volume":"25","author":"JW Mays","year":"2019","unstructured":"Mays JW, Carey BP, Posey R, et al. World workshop of oral medicine VII: a systematic review of immunobiologic therapy for oral manifestations of pemphigoid and pemphigus. Oral Dis. 2019;25(Suppl 1(Suppl 1)):111\u201321. https:\/\/doi.org\/10.1111\/odi.13083.","journal-title":"Oral Dis"},{"key":"1478_CR13","doi-asserted-by":"publisher","unstructured":"Kirtschig G, Middleton P, Bennett C. ... Interventions for bullous pemphigoid. Cochrane Database \u2026. 2010. (Query date: 2021-01-22 20:49:30). https:\/\/doi.org\/10.1002\/14651858.CD002292.pub3\/abstract.","DOI":"10.1002\/14651858.CD002292.pub3\/abstract"},{"issue":"7","key":"1478_CR14","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","volume":"169","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, Lillie E, Zarin W, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169(7):467\u201373. https:\/\/doi.org\/10.7326\/M18-0850.","journal-title":"Ann Intern Med"},{"key":"1478_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2535","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009. https:\/\/doi.org\/10.1136\/bmj.b2535.","journal-title":"BMJ"},{"issue":"1","key":"1478_CR16","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1093\/bjd\/ljad077","volume":"189","author":"EWH Korte","year":"2023","unstructured":"Korte EWH, Welponer T, Kottner J, et al. Heterogeneity of reported outcomes in epidermolysis bullosa clinical research: a scoping review as a first step towards outcome harmonization. Br J Dermatol. 2023;189(1):80\u201390. https:\/\/doi.org\/10.1093\/bjd\/ljad077.","journal-title":"Br J Dermatol"},{"key":"1478_CR17","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jclinepi.2017.12.020","volume":"96","author":"S Dodd","year":"2018","unstructured":"Dodd S, Clarke M, Becker L, Mavergames C, Fish R, Williamson PR. A taxonomy has been developed for outcomes in medical research to help improve knowledge discovery. J Clin Epidemiol. 2018;96:84\u201392. https:\/\/doi.org\/10.1016\/j.jclinepi.2017.12.020.","journal-title":"J Clin Epidemiol"},{"key":"1478_CR18","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jclinepi.2016.01.021","volume":"75","author":"J McGowan","year":"2016","unstructured":"McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS peer review of electronic search strategies: 2015 guideline statement. J Clin Epidemiol. 2016;75:40\u20136. https:\/\/doi.org\/10.1016\/j.jclinepi.2016.01.021.","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"1478_CR19","doi-asserted-by":"publisher","first-page":"240","DOI":"10.3163\/1536-5050.104.3.014","volume":"104","author":"WM Bramer","year":"2016","unstructured":"Bramer WM, Giustini D, de Jonge GB, Holland L, Bekhuis T. De-duplication of database search results for systematic reviews in EndNote. J Med Libr Assoc. 2016;104(3):240\u20133. https:\/\/doi.org\/10.3163\/1536-5050.104.3.014.","journal-title":"J Med Libr Assoc"},{"issue":"1","key":"1478_CR20","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4.","journal-title":"Syst Rev"},{"key":"1478_CR21","unstructured":"Shetty S, Ahmed A. Critical analysis of the use of rituximab in mucous membrane pemphigoid: a review of the literature. J Am Acad Dermatol. 2013;(Query date: 2021-01-22 20:49:30). https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0190962212011450"},{"issue":"4","key":"1478_CR22","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.ophtha.2007.10.029","volume":"115","author":"MD Mignogna","year":"2008","unstructured":"Mignogna MD, Leuci S, Piscopo R, Bonovolont\u00e0 G. Intravenous immunoglobulins and mucous membrane pemphigoid. Ophthalmology. 2008;115(4):752-752.e1. https:\/\/doi.org\/10.1016\/j.ophtha.2007.10.029.","journal-title":"Ophthalmology"},{"issue":"7","key":"1478_CR23","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/archdermatol.2011.54","volume":"147","author":"C Le Roux-Villet","year":"2011","unstructured":"Le Roux-Villet C, Prost-Squarcioni C, Alexandre M, et al. Rituximab for patients with refractory mucous membrane pemphigoid. Arch Dermatol. 2011;147(7):843\u20139. https:\/\/doi.org\/10.1001\/archdermatol.2011.54.","journal-title":"Arch Dermatol"},{"issue":"6","key":"1478_CR24","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1111\/jdv.12175","volume":"28","author":"M Kolesnik","year":"2014","unstructured":"Kolesnik M, Becker E, Reinhold D, et al. Treatment of severe autoimmune blistering skin diseases with combination of protein A immunoadsorption and rituximab: a protocol without initial high dose or pulse steroid medication. J Eur Acad Dermatol Venereol. 2014;28(6):771\u201380. https:\/\/doi.org\/10.1111\/jdv.12175.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1478_CR25","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.jaad.2010.07.032","volume":"65","author":"M Kasperkiewicz","year":"2011","unstructured":"Kasperkiewicz M, Shimanovich I, Ludwig RJ, Rose C, Zillikens D, Schmidt E. Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients. J Am Acad Dermatol. 2011;65(3):552\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2010.07.032.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1478_CR26","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.jaad.2013.01.046","volume":"69","author":"K Heelan","year":"2013","unstructured":"Heelan K, Walsh S, Shear NH. Treatment of mucous membrane pemphigoid with rituximab. J Am Acad Dermatol. 2013;69(2):310\u20131. https:\/\/doi.org\/10.1016\/j.jaad.2013.01.046.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1478_CR27","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2165\/11533290-000000000-00000","volume":"11","author":"HM G\u00fcrcan","year":"2010","unstructured":"G\u00fcrcan HM, Jeph S, Ahmed AR. Intravenous immunoglobulin therapy in autoimmune mucocutaneous blistering diseases: a review of the evidence for its efficacy and safety. Am J Clin Dermatol. 2010;11(5):315\u201326. https:\/\/doi.org\/10.2165\/11533290-000000000-00000.","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"1478_CR28","doi-asserted-by":"publisher","first-page":"383","DOI":"10.2165\/11310740-000000000-00000","volume":"10","author":"HM G\u00fcrcan","year":"2009","unstructured":"G\u00fcrcan HM, Ahmed AR. Efficacy of dapsone in the treatment of pemphigus and pemphigoid: analysis of current data. Am J Clin Dermatol. 2009;10(6):383\u201396. https:\/\/doi.org\/10.2165\/11310740-000000000-00000.","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"1478_CR29","doi-asserted-by":"publisher","first-page":"529","DOI":"10.5301\/EJO.2011.6294","volume":"21","author":"MA El Darouti","year":"2011","unstructured":"El Darouti MA, Fakhry Khattab MA, Hegazy RA, Hafez DA, Gawdat HI. Pentoxifylline (anti-tumor necrosis factor drug): effective adjuvant therapy in the control of ocular cicatricial pemphigoid. Eur J Ophthalmol. 2011;21(5):529\u201337. https:\/\/doi.org\/10.5301\/EJO.2011.6294.","journal-title":"Eur J Ophthalmol"},{"issue":"6","key":"1478_CR30","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1111\/j.1600-0714.2008.00653.x","volume":"37","author":"A Arash","year":"2008","unstructured":"Arash A, Shirin L. The management of oral mucous membrane pemphigoid with dapsone and topical corticosteroid. J Oral Pathol Med. 2008;37(6):341\u20134. https:\/\/doi.org\/10.1111\/j.1600-0714.2008.00653.x.","journal-title":"J Oral Pathol Med"},{"issue":"8","key":"1478_CR31","doi-asserted-by":"publisher","first-page":"e321","DOI":"10.1111\/jdv.14873","volume":"32","author":"M Witte","year":"2018","unstructured":"Witte M, Zillikens D, Shimanovich I. Intravenous immunoglobulins for rituximab-resistant mucous membrane pemphigoid. J Eur Acad Dermatol Venereol JEADV. 2018;32(8):e321\u20134. https:\/\/doi.org\/10.1111\/jdv.14873.","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"key":"1478_CR32","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13307","author":"D Tomsitz","year":"2015","unstructured":"Tomsitz D, Stefaniak R, Worm M. Rituximab in patients with recalcitrant autoimmune blistering diseases: experience in a cohort of 22 patients. Br J Dermatol. 2015. https:\/\/doi.org\/10.1111\/bjd.13307.","journal-title":"Br J Dermatol"},{"key":"1478_CR33","doi-asserted-by":"publisher","first-page":"37","DOI":"10.4103\/1735-1995.183992","volume":"21","author":"S Tavakolpour","year":"2016","unstructured":"Tavakolpour S. The role of intravenous immunoglobulin in treatment of mucous membrane pemphigoid: a review of literature. J Res Med Sci. 2016;21:37. https:\/\/doi.org\/10.4103\/1735-1995.183992.","journal-title":"J Res Med Sci"},{"issue":"4","key":"1478_CR34","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1111\/bjd.20493","volume":"185","author":"C Riquelme-Mc Loughlin","year":"2021","unstructured":"Riquelme-Mc Loughlin C, Iranzo P. Subcutaneous rituximab for autoimmune bullous diseases. Br J Dermatol. 2021;185(4):870\u20131. https:\/\/doi.org\/10.1111\/bjd.20493.","journal-title":"Br J Dermatol"},{"key":"1478_CR35","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jdin.2021.09.003","volume":"6","author":"Y Liang","year":"2022","unstructured":"Liang Y, Zeng FAP, Sheriff T, et al. Evaluation of the toxicity of glucocorticoids in patients with autoimmune blistering disease using the Glucocorticoid Toxicity Index: a cohort study. JAAD Int. 2022;6:68\u201376. https:\/\/doi.org\/10.1016\/j.jdin.2021.09.003.","journal-title":"JAAD Int"},{"issue":"2","key":"1478_CR36","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s00403-021-02216-z","volume":"314","author":"XX Jin","year":"2022","unstructured":"Jin XX, Wang X, Shan Y, et al. Efficacy and safety of tetracyclines for pemphigoid: a systematic review and meta-analysis. Arch Dermatol Res. 2022;314(2):191\u2013201. https:\/\/doi.org\/10.1007\/s00403-021-02216-z.","journal-title":"Arch Dermatol Res"},{"issue":"10","key":"1478_CR37","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1097\/ICO.0000000000000168","volume":"33","author":"J Friedman","year":"2014","unstructured":"Friedman J, Marcovich AL, Kleinmann G, Schattner A. Low-dose pulsed intravenous cyclophosphamide for severe ocular cicatricial pemphigoid in elderly patients. Cornea. 2014;33(10):1066\u201370. https:\/\/doi.org\/10.1097\/ICO.0000000000000168.","journal-title":"Cornea"},{"issue":"6","key":"1478_CR38","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.jaad.2021.06.862","volume":"86","author":"A Mohammed","year":"2022","unstructured":"Mohammed A, Hekman D, Li W, Misquith C, Rahnama-Moghadam S. The safety of rituximab for the treatment of autoimmune blistering diseases: a systematic review. J Am Acad Dermatol. 2022;86(6):1439\u201344. https:\/\/doi.org\/10.1016\/j.jaad.2021.06.862.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1478_CR39","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.clim.2004.04.010","volume":"112","author":"SW Yeh","year":"2004","unstructured":"Yeh SW, Usman AQ, Ahmed AR. Profile of autoantibody to basement membrane zone proteins in patients with mucous membrane pemphigoid: long-term follow up and influence of therapy. Clin Immunol. 2004;112(3):268\u201372. https:\/\/doi.org\/10.1016\/j.clim.2004.04.010.","journal-title":"Clin Immunol"},{"key":"1478_CR40","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07646.x","author":"E Schmidt","year":"2006","unstructured":"Schmidt E, Seitz CS, Benoit S, Br\u00f6cker EB, Goebeler M. Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br J Dermatol. 2006. https:\/\/doi.org\/10.1111\/j.1365-2133.2006.07646.x.","journal-title":"Br J Dermatol"},{"issue":"7","key":"1478_CR41","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.ophtha.2003.11.012","volume":"111","author":"N Sami","year":"2004","unstructured":"Sami N, Letko E, Androudi S, Daoud Y, Foster CS, Ahmed AR. Intravenous immunoglobulin therapy in patients with ocular-cicatricial pemphigoid: a long-term follow-up. Ophthalmology. 2004;111(7):1380\u20132. https:\/\/doi.org\/10.1016\/j.ophtha.2003.11.012.","journal-title":"Ophthalmology"},{"issue":"1","key":"1478_CR42","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1006\/clim.2001.5150","volume":"102","author":"N Sami","year":"2002","unstructured":"Sami N, Bhol KC, Razzaque Ahmed A. Intravenous immunoglobulin therapy in patients with multiple mucosal involvement in mucous membrane pemphigoid. Clin Immunol Orlando Fla. 2002;102(1):59\u201367. https:\/\/doi.org\/10.1006\/clim.2001.5150.","journal-title":"Clin Immunol Orlando Fla"},{"issue":"3","key":"1478_CR43","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1046\/j.1365-2249.2002.01942.x","volume":"129","author":"N Sami","year":"2002","unstructured":"Sami N, Bhol KC, Ahmed AR. Treatment of oral pemphigoid with intravenous immunoglobulin as monotherapy. Long-term follow-up: influence of treatment on antibody titres to human alpha6 integrin. Clin Exp Immunol. 2002;129(3):533\u201340. https:\/\/doi.org\/10.1046\/j.1365-2249.2002.01942.x.","journal-title":"Clin Exp Immunol"},{"issue":"6","key":"1478_CR44","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1080\/09546630600964999","volume":"17","author":"AV Marzano","year":"2006","unstructured":"Marzano AV, Dassoni F, Caputo R. Treatment of refractory blistering autoimmune diseases with mycophenolic acid. J Dermatol Treat. 2006;17(6):370\u20136. https:\/\/doi.org\/10.1080\/09546630600964999.","journal-title":"J Dermatol Treat"},{"issue":"3","key":"1478_CR45","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.clim.2003.11.002","volume":"111","author":"E Letko","year":"2004","unstructured":"Letko E, Miserocchi E, Daoud YJ, Christen W, Foster CS, Ahmed AR. A nonrandomized comparison of the clinical outcome of ocular involvement in patients with mucous membrane (cicatricial) pemphigoid between conventional immunosuppressive and intravenous immunoglobulin therapies. Clin Immunol Orlando Fla. 2004;111(3):303\u201310. https:\/\/doi.org\/10.1016\/j.clim.2003.11.002.","journal-title":"Clin Immunol Orlando Fla"},{"key":"1478_CR46","unstructured":"Kirtschig G, Murrell D, Wojnarowska F. Interventions for mucous membrane pemphigoid\/cicatricial pemphigoid and epidermolysis bullosa acquisita: a systematic literature review. Arch \u2026. 2002;(Query date: 2021-01-22 20:49:30). https:\/\/jamanetwork.com\/journals\/jamadermatology\/article-abstract\/478709."},{"issue":"6","key":"1478_CR47","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1067\/moe.2003.139","volume":"95","author":"MA Gonzalez-Moles","year":"2003","unstructured":"Gonzalez-Moles MA, Ruiz-Avila I, Rodriguez-Archilla A, et al. Treatment of severe erosive gingival lesions by topical application of clobetasol propionate in custom trays. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003;95(6):688\u201392. https:\/\/doi.org\/10.1067\/moe.2003.139.","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"issue":"3","key":"1478_CR48","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/S0161-6420(02)01892-4","volume":"110","author":"S Barabino","year":"2003","unstructured":"Barabino S, Rolando M, Bentivoglio G, et al. Role of amniotic membrane transplantation for conjunctival reconstruction in ocular-cicatricial pemphigoid. Ophthalmology. 2003;110(3):474\u201380. https:\/\/doi.org\/10.1016\/S0161-6420(02)01892-4.","journal-title":"Ophthalmology"},{"issue":"1","key":"1478_CR49","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1159\/000526600","volume":"239","author":"WH Tan","year":"2023","unstructured":"Tan WH, Sim J, Sultana R, Lee HY. Rituximab in subepidermal blistering diseases. Dermatology. 2023;239(1):5\u201311. https:\/\/doi.org\/10.1159\/000526600.","journal-title":"Dermatology"},{"issue":"8","key":"1478_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2022.103119","volume":"21","author":"MM Farooq","year":"2022","unstructured":"Farooq MM, Miloslavsky EM, Konikov N, Ahmed AR. Use of rituximab in the treatment of mucous membrane pemphigoid: an analytic review. Autoimmun Rev. 2022;21(8):103119. https:\/\/doi.org\/10.1016\/j.autrev.2022.103119.","journal-title":"Autoimmun Rev"},{"key":"1478_CR51","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14829","author":"N Kianfar","year":"2023","unstructured":"Kianfar N, Dasdar S, Daneshpazhooh M, Aryanian Z, Goodarzi A. A systematic review on efficacy, safety and treatment durability of intravenous immunoglobulin in autoimmune bullous dermatoses: special focus on indication and combination therapy. Exp Dermatol. 2023. https:\/\/doi.org\/10.1111\/exd.14829.","journal-title":"Exp Dermatol"},{"key":"1478_CR52","first-page":"527","volume":"84","author":"CS Foster","year":"1986","unstructured":"Foster CS. Cicatricial pemphigoid. Trans Am Ophthalmol Soc. 1986;84:527\u2013663.","journal-title":"Trans Am Ophthalmol Soc"},{"issue":"5","key":"1478_CR53","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1097\/00003226-199209000-00015","volume":"11","author":"J Tauber","year":"1992","unstructured":"Tauber J, Jabbur N, Foster CS. Improved detection of disease progression in ocular cicatricial pemphigoid. Cornea. 1992;11(5):446\u201351. https:\/\/doi.org\/10.1097\/00003226-199209000-00015.","journal-title":"Cornea"},{"issue":"3","key":"1478_CR54","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.jaad.2011.06.032","volume":"66","author":"DF Murrell","year":"2012","unstructured":"Murrell DF, Daniel BS, Joly P, et al. Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts. J Am Acad Dermatol. 2012;66(3):479\u201385. https:\/\/doi.org\/10.1016\/j.jaad.2011.06.032.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1478_CR55","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1684\/ejd.2007.0090","volume":"17","author":"M Pf\u00fctze","year":"2007","unstructured":"Pf\u00fctze M, Niedermeier A, Hertl M, Eming R. Introducing a novel autoimmune bullous skin disorder intensity score (ABSIS) in pemphigus. Eur J Dermatol EJD. 2007;17(1):4\u201311. https:\/\/doi.org\/10.1684\/ejd.2007.0090.","journal-title":"Eur J Dermatol EJD."},{"issue":"10","key":"1478_CR56","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1001\/jamadermatol.2013.4972","volume":"149","author":"DF Sebaratnam","year":"2013","unstructured":"Sebaratnam DF, Hanna AM, Chee S, et al. Development of a quality-of-life instrument for autoimmune bullous disease: the autoimmune bullous disease quality of life questionnaire. JAMA Dermatol. 2013;149(10):1186\u201391. https:\/\/doi.org\/10.1001\/jamadermatol.2013.4972.","journal-title":"JAMA Dermatol"},{"issue":"5","key":"1478_CR57","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1111\/bjd.12623","volume":"169","author":"A Tjokrowidjaja","year":"2013","unstructured":"Tjokrowidjaja A, Daniel BS, Frew JW, et al. The development and validation of the treatment of autoimmune bullous disease quality of life questionnaire, a tool to measure the quality of life impacts of treatments used in patients with autoimmune blistering disease. Br J Dermatol. 2013;169(5):1000\u20136. https:\/\/doi.org\/10.1111\/bjd.12623.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1478_CR58","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/bjd.18566","volume":"183","author":"M Ormond","year":"2020","unstructured":"Ormond M, McParland H, Thakrar P, et al. Validation of an oral disease severity score (ODSS) tool for use in oral mucous membrane pemphigoid. Br J Dermatol. 2020;183(1):78\u201385. https:\/\/doi.org\/10.1111\/bjd.18566.","journal-title":"Br J Dermatol"},{"key":"1478_CR59","unstructured":"COSMIN\u2014improving the selection of outcome measurement instruments. COSMIN. https:\/\/www.cosmin.nl\/. Accessed 1 Nov 2024."},{"issue":"5","key":"1478_CR60","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1111\/bjd.19173","volume":"183","author":"L Ferries","year":"2020","unstructured":"Ferries L, Gillibert A, Duvert-Lehembre S, et al. Sensitivity to change and correlation between the autoimmune bullous disease quality-of-life questionnaires ABQOL and TABQOL, and objective severity scores. Br J Dermatol. 2020;183(5):944\u20135. https:\/\/doi.org\/10.1111\/bjd.19173.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1478_CR61","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1016\/j.jaad.2022.04.042","volume":"87","author":"A Garg","year":"2022","unstructured":"Garg A, Dirr MA, Jemec GBE, et al. Shifting focus from \u201cwhat we do\u201d to the \u201cimpact of what we do\u201d: application of outcome measures to routine clinical care in dermatology. J Am Acad Dermatol. 2022;87(2):e83\u20134. https:\/\/doi.org\/10.1016\/j.jaad.2022.04.042.","journal-title":"J Am Acad Dermatol"},{"key":"1478_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2024.111277","volume":"169","author":"IJ Saldanha","year":"2024","unstructured":"Saldanha IJ, Hughes KL, Dodd S, et al. Study found increasing use of core outcome sets in Cochrane systematic reviews and identified facilitators and barriers. J Clin Epidemiol. 2024;169:111277. https:\/\/doi.org\/10.1016\/j.jclinepi.2024.111277.","journal-title":"J Clin Epidemiol"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01478-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-025-01478-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01478-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:57:35Z","timestamp":1760774255000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-025-01478-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,23]]},"references-count":62,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1478"],"URL":"https:\/\/doi.org\/10.1007\/s40261-025-01478-z","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"type":"print","value":"1173-2563"},{"type":"electronic","value":"1179-1918"}],"subject":[],"published":{"date-parts":[[2025,9,23]]},"assertion":[{"value":"8 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"BT, EK, MH, SW have no relevant conflicts to declare. B. Horv\u00e1th reports fees from Janssen-Cilag (Advisory Boards, Educational grants, Consultations, Investigator Initiative Studies), AbbVie (Advisory Boards, Educational grants, Consultations, Investigator Initiative Studies), Novartis Pharma (Advisory Boards, Consultations, Investigator Initiative Studies), UCB Pharma (Advisory Boards, Consultations), Leo Pharma (Consultations), Solenne B.V. (Investigator Initiative Studies), Celgene (Consultations, Investigator Initiative Studies), Akari therapeutics (Consultations, Investigator Initiative Studies), Philips (Consultation), Roche (Consultation), Regeneron (Consultation) and Sanofi (Consultation), Argenx (Advisory Boards, Consultations) and Boehringer-Ingelheim (Advisory Boards, Consultations). All contracts were reviewed by the Board of Directors of the UMCG, and all fees were paid to the institution. J. Meijer reports fees from Argenx (Advisory Boards, Consultations), Sanofi (Consultation), Janssen-Cilag (Consultation). All contracts were reviewed by the Board of Directors of the UMCG, and all fees were paid to the institution. MB reports fees from Krystal Biotech (advisory board, consultations), Chiesi (consultations) and Janssen-Cilag (payment for education development). All contracts were reviewed by the Board of Directors of the UMCG, and all fees were paid to the institution. PS receives departmental independent research grants for TREAT NL registry from Pharma since December 2019, is Chief Investigator (CI) of the systemic and phototherapy atopic eczema registry (TREAT NL\/BE) for adults and children, and project lead of the governmental funded UPDATE trial. She is involved in performing clinical trials with many pharmaceutical industries that manufacture drugs used for the treatment of e.g., psoriasis and atopic dermatitis, for which financial compensation is paid to the department\/hospital. She was involved in the development of one of the HOME core outcome instruments (Recap of atopic eczema (RECAP)), and in the development of the Outcome Measures for VAscular Malformations (OVAMA) questionnaire for vascular malformations. P. Joly is consultant for Amgen, Argenx, Astra Zeneca, Thermofisher, Sanofi, Akari, Janssen, Novartis, Servier, Chugai, Kezar Life Science, Regeneron, UCB, Principabio, Zenyaku Kogyo, Dualyx, Amgen, JJP Biologics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No ethics approval is required for this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Data are available upon reasonable request to the corresponding author.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Conceptualization: BT, EWHK, BH, PJ. Data acquisition: BT, EWHK, MAJH. Data analysis and interpretation: BT, EWHK, MAJH. Manuscript drafting: BT, EWHK. Critical revision of the manuscript for important intellectual content: EWHK, MAJH, JMM, MCB, PIS, SW, MY, BH, PJ. Supervision: PJ, BH. BT and EWHK contributed equally to this work and should be considered joint first authors. BH and PJ share joint senior authorship. All authors read and approved the final version.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}